![DISRUPTLogo-MedHorizontal[1].png](https://static.wixstatic.com/media/1ad237_0694e719fff24e1b99901c9a23a001c1~mv2.png/v1/fill/w_130,h_50,al_c,q_85,usm_0.66_1.00_0.01,enc_avif,quality_auto/DISRUPTLogo-MedHorizontal%5B1%5D.png)
![DISRUPTLogo-MedHorizontal[1].png](https://static.wixstatic.com/media/1ad237_0694e719fff24e1b99901c9a23a001c1~mv2.png/v1/fill/w_500,h_200,al_c,q_85,usm_0.66_1.00_0.01,enc_avif,quality_auto/DISRUPTLogo-MedHorizontal%5B1%5D.png)
A First-in-human, Multicenter, Open-label, Dose Escalation and Dose Expansion Phase 1 Study in Patients with Advanced Solid Tumors to Evaluate the Safety of Intravenously Administered ALG.APV-527
In this new study across multiple hospitals, researchers are investigating the safety of ALG.APV-527, a medication administered through a vein, in individuals with advanced solid tumors. The study involves gradually increasing the dose of the medication to find the highest amount that is safe for patients. By evaluating the safety of ALG.APV-527 in this Phase 1 study, researchers hope to pave the way for future investigations into its effectiveness against advanced solid tumors.
Phase 1: First step in testing a new medicine in people, and tests if treatment is safe, determines the right dose, and checks for any side effects. |
For more information about the trial, click the link below:
Clinical Trial Site: Sinai
To see all available clinical trials click here.
Comments